Section 781 and CBD for Pets: What Every Pet Owner Needs to Know

If you give your pet CBD, or you are thinking about it, the regulatory picture is about to change in ways that affect every product on the market, every veterinarian you might ask about it, and every decision you make at checkout.

Section 781 of the FDA Modernization Act is the first federal law that directly addresses CBD for animals. It sets a November 2026 deadline for the FDA to establish a formal regulatory framework. And the expected rules, particularly a THC threshold so low it would eliminate most full-spectrum products, will reshape the market from the ground up.

This guide covers the full regulatory picture: the history that led us here, what the law actually says, how it interacts with state regulations and industry bodies, and what it means for pet owners, veterinarians, and brands. If you are looking for a shorter take on which products survive the THC math, see our companion piece on whether CBD pet products are becoming illegal. This page is the complete reference.

The Regulatory Timeline: How We Got Here

Understanding why Section 781 matters requires understanding the regulatory vacuum it fills. CBD for pets has never been explicitly legal or illegal at the federal level. It has existed in a gray zone created by overlapping and sometimes contradictory laws.

Before 2018: CBD Was Federally Illegal

Prior to the 2018 Farm Bill, all cannabis-derived compounds, including CBD, were classified as Schedule I controlled substances under the Controlled Substances Act. Hemp and marijuana were not legally distinguished. Any product containing cannabidiol, regardless of THC content, was federally illegal to manufacture, sell, or distribute.

In practice, the market existed anyway. CBD pet products were sold online and in stores, particularly in states with legal cannabis frameworks. But there was no federal legal basis for these products, and manufacturers operated at their own risk.

2018: The Farm Bill Changes Everything (and Nothing)

The Agriculture Improvement Act of 2018 (commonly called the 2018 Farm Bill) removed hemp from the Controlled Substances Act. Hemp was legally defined as cannabis containing less than 0.3% THC by dry weight. Overnight, hemp-derived CBD became federally legal to grow and extract.

But the Farm Bill did not legalize CBD as a food ingredient, dietary supplement, or animal feed additive. It legalized the plant. The FDA retained authority over how cannabinoid products could be marketed and sold. And the FDA's position, stated repeatedly in warning letters and public guidance, was that CBD could not be legally added to food, beverages, dietary supplements, or animal products without FDA approval.

This created the gray zone. The raw material was legal. The finished products were technically not approved. But the FDA lacked the resources and political will to enforce against an exploding market. Pet CBD products proliferated. By some industry estimates, the pet CBD market exceeded $500 million within three years of the Farm Bill's passage.

2019–2023: The FDA Does Very Little

During this period, the FDA's approach to CBD regulation was characterized by inaction punctuated by occasional warning letters. The agency:

• Issued warning letters to companies making specific medical claims about CBD (e.g., "cures cancer," "treats epilepsy") but did not pursue enforcement against the broader market
• Held public hearings in 2019 where thousands of comments were submitted, but no rulemaking followed
• Published consumer advisories cautioning about the lack of safety data, particularly for pregnant women and children, but said little about animals specifically
• Acknowledged that the current regulatory framework was inadequate for CBD products but offered no timeline for a new one
• In January 2023, formally stated it would not pursue traditional food/supplement rulemaking for CBD and called on Congress to create a new legislative pathway

For pet owners, this meant the products you were buying had no federal quality standards, no required testing, no labeling accuracy requirements, and no enforcement mechanism if a product was mislabeled or contaminated. The market was functionally unregulated.

2024: Congress Acts with Section 781

Section 781 of the FDA Modernization Act responded to the FDA's request for Congressional action. For the first time, federal law directly addressed cannabidiol products for animal use. Rather than waiting for the FDA to develop its own framework through the traditional (and glacially slow) rulemaking process, Congress mandated one.

What Section 781 Actually Says

Section 781 is part of a larger FDA reauthorization package. Its core provisions, in plain English:

The Mandate

The FDA is directed (not asked, not encouraged, directed) to establish a regulatory framework for cannabidiol products intended for use in animals. This is a Congressional mandate with a statutory deadline. The distinction matters because the FDA's previous position was that it lacked adequate authority to regulate CBD under existing food and drug law. Congress is now providing that authority and requiring action.

The Deadline

November 2026. The framework must be established by this date. "Established" in legislative context typically means published as a final rule or interim final rule in the Federal Register, though the exact form the framework takes may vary.

Will the FDA meet this deadline? History suggests it may not. The agency regularly misses Congressional deadlines for rulemaking. The 2018 Farm Bill implicitly expected FDA action on CBD within a reasonable timeframe, and five years later the agency had done nothing. However, Section 781 is more prescriptive than the Farm Bill's general authorization. The explicit deadline and the growing political pressure around CBD regulation make some form of framework by late 2026 or early 2027 a reasonable expectation.

The Scope

Section 781 covers cannabidiol products for animal use specifically. This means:

• CBD pet supplements, treats, oils, and topicals are within scope
• Products marketed for companion animals (dogs, cats, horses) are directly affected
• Products marketed for livestock may face additional USDA requirements beyond the FDA framework
• Human CBD products are governed by separate regulatory proceedings

The THC Threshold

The expected framework includes a total THC limit of 0.4 mg per container. This is the single most consequential provision because it shifts the measurement standard from percentage-of-plant-weight (the Farm Bill's 0.3% standard) to total milligrams per finished product. As we detail in our companion analysis, this eliminates approximately 95% of current full-spectrum CBD pet products.

What Section 781 Does NOT Do

• Does not ban CBD for pets. It creates a legal pathway, not a prohibition.
• Does not make it illegal to give your pet CBD. The regulation targets manufacturers, not consumers.
• Does not require a prescription. CBD products that meet the new standards would remain available over the counter.
• Does not create FDA approval for CBD as a veterinary drug. The framework governs CBD as an animal supplement or feed ingredient, not as a pharmaceutical.
• Does not preempt state law. States retain the ability to impose stricter (or looser) requirements within their borders.

The THC Math: 0.4 mg Per Container

The 0.4 mg total-THC-per-container threshold deserves detailed examination because it fundamentally changes which products can exist on the market.

Why Per-Container, Not Percentage?

The 2018 Farm Bill uses a percentage standard: hemp must contain less than 0.3% THC by dry weight. This works for agricultural regulation: it tells farmers and processors how much THC is acceptable in the raw plant. But it fails as a consumer protection standard because a product can be 0.3% THC and still contain significant total THC depending on the volume.

A per-container standard measures what the consumer actually receives. It accounts for product size, concentration, and total cannabinoid content. It is the same approach the FDA uses for other regulated substances in foods and supplements: total amount per serving or per package, not percentage of the formulation.

What This Means by Product Type

The pattern is clear: at standard CBD concentrations, full-spectrum products contain too much total THC. The higher the potency and the larger the container, the worse the math. Only products that actively remove THC (broad-spectrum and isolate) or contain very small total cannabinoid loads can comply.

For a walkthrough of which specific product types survive, see our detailed compliance analysis.

The FDA's Historical Stance on CBD for Animals

The FDA's relationship with pet CBD has been defined by three consistent positions:

Position 1: CBD Is Not an Approved Animal Drug

CBD is not FDA-approved for any veterinary indication. The only FDA-approved cannabidiol product is Epidiolex (human epilepsy medication). No animal-specific CBD product has gone through the FDA's drug approval process, which requires preclinical studies, clinical trials, and a New Animal Drug Application (NADA).

This means no CBD pet product can legally claim to treat, cure, mitigate, or prevent any disease or condition. Products making such claims have been the primary target of FDA warning letters.

Position 2: CBD Cannot Be Added to Animal Food Without Approval

Under the Federal Food, Drug, and Cosmetic Act, any substance added to animal food must be either an approved food additive or Generally Recognized as Safe (GRAS). CBD is neither. The FDA has repeatedly stated that adding CBD to animal food renders that food adulterated under federal law.

In practice, this means every CBD treat, every CBD-infused chew, and every CBD supplement marketed as a food product for animals exists in technical violation of FDA rules. The agency has not broadly enforced this position, but it remains the legal baseline.

Position 3: More Safety Data Is Needed

The FDA has consistently stated that insufficient safety data exists to establish CBD as safe for animals, particularly regarding long-term use, effects on reproduction, and interactions with veterinary pharmaceuticals. This position has softened somewhat as published veterinary studies have accumulated, but it remains the agency's official stance.

Section 781 effectively overrides the FDA's inaction by mandating a framework regardless of whether the agency believes the data is sufficient. Congress is forcing the issue.

AAFCO: Why This Industry Body Matters

The Association of American Feed Control Officials (AAFCO) is not a government agency. It is an organization of state, federal, and international feed regulators that establishes model regulations and ingredient definitions for animal feed and pet food. Understanding AAFCO's role is essential because most states adopt AAFCO's model regulations as state law.

AAFCO's Current Position on CBD

AAFCO does not recognize CBD as an approved animal feed ingredient. This means:

• CBD cannot be listed as an ingredient in pet food or treats under AAFCO model regulations
• States that follow AAFCO standards may consider CBD pet products adulterated
• Products marketed as "pet food" or "animal treats" containing CBD face a compliance challenge at the state level even if federal law changes

Why AAFCO's Position Matters for Section 781

Even after the FDA establishes its federal framework, AAFCO's ingredient definitions will determine how CBD can be labeled and marketed at the state level. If AAFCO adopts CBD as a recognized ingredient, aligned with the FDA framework, the path to market normalizes rapidly. If AAFCO does not, manufacturers face a patchwork of state-level compliance requirements even if they meet federal standards.

AAFCO has been monitoring CBD developments and is expected to take action following the FDA's framework publication. The timeline and specifics of AAFCO's response are not yet known.

NASC: The Voluntary Quality Seal

The National Animal Supplement Council (NASC) is a nonprofit industry group that provides a voluntary quality assurance program for animal health supplements. You may have seen the NASC Quality Seal on some CBD pet products. Here is what it means and what it does not mean.

What the NASC Seal Indicates

• The manufacturer has passed an independent quality audit of its facilities and processes
• The product carries liability insurance
• The manufacturer maintains an adverse event reporting system and reports adverse events to the FDA
• Labels have been reviewed for compliance with NASC labeling guidelines
• The manufacturer has agreed to random product testing by NASC

What the NASC Seal Does NOT Indicate

• It is not FDA approval
• It does not verify that the product works for any specific condition
• It does not guarantee label accuracy for cannabinoid content (though random testing may catch discrepancies)
• It does not mean the product meets Section 781 requirements (which do not yet exist as enforceable rules)
• It is voluntary, and many legitimate CBD brands do not participate in the NASC program

State-by-State Regulatory Landscape

Federal law sets the floor. States can be more permissive or more restrictive. The result is a patchwork of regulations that varies significantly depending on where you live and where you buy.

States with Explicit CBD Pet Product Frameworks

A small number of states have enacted legislation or regulatory guidance specifically addressing CBD in animal products. These states generally permit CBD pet products that meet certain requirements (THC limits, testing, labeling). Examples include states with established hemp programs that have extended their rules to finished pet products.

States That Follow AAFCO Strictly

Many states adopt AAFCO model regulations without modification. Because AAFCO does not recognize CBD as an approved ingredient, these states may technically consider CBD pet products to be adulterated animal feed. In practice, enforcement has been minimal, but the legal risk exists, particularly for retailers and manufacturers operating in those states.

States That Are Silent

Some states have no specific guidance on CBD in animal products. Products are sold freely, but without a regulatory framework, there are no state-level protections for consumers if a product is mislabeled, contaminated, or ineffective.

States with Restrictive Positions

A few states have taken more restrictive positions, including issuing guidance that CBD pet products are not permitted for sale, or requiring specific licenses for manufacturers and retailers. These positions may change as federal regulation provides a clearer legal baseline.

How Section 781 Affects Veterinarians

If you have asked your veterinarian about CBD and received a vague or noncommittal answer, you experienced the regulatory problem firsthand.

The Current Legal Ambiguity

Veterinarians operate under state veterinary practice acts, which define what constitutes the practice of veterinary medicine within each state. In most states, the legal situation around CBD and veterinary practice includes these complications:

• Recommending vs. prescribing. CBD is not an approved drug, so it cannot be "prescribed" in the pharmaceutical sense. But can a veterinarian "recommend" it? The answer varies by state and by interpretation. Some state veterinary boards have issued guidance; many have not.
• The extra-label use question. Veterinarians commonly use approved drugs for unapproved ("extra-label") purposes under the Animal Medicinal Drug Use Clarification Act (AMDUCA). But this only applies to FDA-approved drugs. CBD is not an approved drug, so AMDUCA does not provide the same legal cover.
• Professional liability. If a veterinarian recommends CBD and the animal has an adverse reaction, the veterinarian may face liability concerns, particularly because the product is not regulated and may not contain what its label claims.
• State board risk. Some veterinarians have expressed concern that actively recommending CBD could attract scrutiny from their state veterinary board, even if no specific prohibition exists.

How Section 781 May Help

A federal regulatory framework for animal CBD products would address several of these concerns:

• Product standardization reduces the risk that a recommended product is mislabeled or contaminated
• A federal legal pathway gives state veterinary boards a reference point for updating their own guidance
• Defined product categories allow veterinarians to discuss specific, compliant products rather than making general "try CBD" recommendations
• Adverse event reporting requirements create a data stream that can inform future veterinary guidance

Section 781 will not resolve every ambiguity in veterinary CBD guidance. Veterinarians will still be operating in a space where CBD is regulated but not approved as a drug. But a formal framework is a significant step toward the clarity that veterinary professionals and their clients need.

How Section 781 Affects Pet Owners

For the average pet owner who buys CBD for their dog or cat, the practical changes fall into three categories.

What Gets Better

• Label accuracy. The current mislabeling rate (56% of CBD pet products, according to Leafreport) is a direct consequence of the absence of regulation. Mandatory testing and labeling standards should significantly reduce this.
• Safety standards. Manufacturing requirements (likely including cGMP compliance) will reduce contamination risk from pesticides, heavy metals, solvents, and microbial agents.
• Product clarity. You will be able to identify which products meet the federal standard and which do not. Compliant products will likely carry labeling that indicates regulatory compliance.
• Veterinary conversations. A clear regulatory framework makes it easier for your veterinarian to discuss CBD with you, even if they cannot formally prescribe it.

What Gets Harder

• Full-spectrum availability. If you currently use full-spectrum CBD for your pet and believe the entourage effect provides benefit, compliant products will no longer contain meaningful THC. The debate about whether this affects therapeutic value is ongoing. See our guide on CBD vs. hemp oil for dogs for more on how extract types differ.
• Price increases. Compliance costs (testing, reformulation, facility upgrades, labeling) will be passed to consumers. Expect CBD pet products to cost more under the new framework, at least initially.
• Fewer choices. Smaller brands that cannot afford compliance may exit the market. Market consolidation is a likely outcome, which may reduce variety but improve average quality.

What to Do Before November 2026

• Learn to read COAs. A Certificate of Analysis from an accredited third-party lab is the single most important document for evaluating any CBD product. It tells you exactly what is in the bottle. Our dosage guide includes a section on reading COA documents.
• Note the total THC in your current product. Look at the COA, find the total THC per container (you may need to calculate it from per-mL values), and compare it to the 0.4 mg threshold. This tells you whether your current product will need to change.
• Consider trying broad-spectrum. If your pet currently takes full-spectrum CBD, a transition to broad-spectrum before the regulatory shift lets you evaluate effectiveness under conditions similar to what compliant products will provide. Many pets show no difference. Our guides to the best CBD treats for dogs and the best CBD oil for cats include broad-spectrum options.
• Talk to your veterinarian. Ask specifically about CBD for your pet's condition. The conversation may be more productive now that a regulatory framework is imminent, and your vet may have updated guidance from their state veterinary board.

How Section 781 Affects CBD Pet Brands

The brand-side impact of Section 781 is significant and will reshape the competitive field.

Reformulation

Any brand selling full-spectrum products must reformulate to remove or reduce THC below the 0.4 mg per-container threshold. This is not a label change; it requires modifying the extraction process, sourcing new raw materials, or adding THC remediation steps. Every SKU must be re-formulated, stability-tested, and re-certified. For brands with dozens of products, this is a multi-month, capital-intensive process.

Testing Requirements

The framework is expected to mandate third-party testing for potency, THC content, pesticides, heavy metals, residual solvents, and microbial contamination. Brands that already test thoroughly will have less to change. Brands that rely on minimal or in-house testing will face significant new costs.

Market Consolidation

Compliance is expensive. Smaller brands operating on thin margins may not survive the transition. This is expected to accelerate market consolidation, with larger, better-capitalized brands absorbing market share from smaller competitors that cannot afford reformulation and testing upgrades.

Brands that already use isolate or verified broad-spectrum extracts are positioned for the least disruption. Brands that have built their identity around full-spectrum and entourage-effect marketing face the most difficult pivot.

The Amazon Factor

Amazon prohibits the sale of CBD products on its platform. Products listed as "hemp oil" or "hemp extract" on Amazon are not, at least officially, CBD products. A federal regulatory framework that defines and standardizes CBD products may actually benefit legitimate CBD brands by drawing a sharper legal line between regulated CBD products and the unregulated "hemp" products that currently dominate Amazon search results. For more on what those Amazon products actually contain, see our hemp oil for dogs guide.

The Case for Regulation

Some pet owners view the incoming regulation with concern -- understandably, since their current products may disappear. But the case for regulation is strong, and it centers on a market that is not serving consumers well.

The Mislabeling Problem

Leafreport's 2020 analysis found that 56% of CBD pet products are mislabeled. Some contain less CBD than advertised. Some contain more THC than listed. Some fail to disclose contaminants detected in third-party testing.

When you buy a bottle of aspirin, you can trust that it contains the stated dose of aspirin. When you buy a bottle of pet CBD, there is a better than one-in-two chance that it does not contain what the label claims. This is not an acceptable standard for a product given to animals.

THC Sensitivity in Dogs

Dogs are significantly more sensitive to THC than humans. They have a higher density of CB1 receptors in the brain, which means THC affects them more intensely at lower doses. THC toxicity in dogs, while rarely fatal, can cause ataxia (loss of coordination), urinary incontinence, excessive drooling, and disorientation. A product that contains more THC than labeled poses a real risk to dogs. For more on THC exposure risks, see our guide on whether dogs can overdose on CBD.

The Quality Floor

Regulation creates a minimum quality standard. Products that cannot meet that standard exit the market. For consumers, this means the average quality of available products goes up, the risk of buying a mislabeled product goes down, and the products that remain can be trusted to contain what they claim.

What We Still Do Not Know

Section 781 provides a mandate and a deadline. It does not provide all the details. Several significant questions remain unanswered.

Enforcement Mechanism

How will the FDA enforce the new framework? Will there be proactive market surveillance and testing? Will enforcement be complaint-driven? Will there be mandatory registration of products or manufacturers? The enforcement approach will determine how quickly non-compliant products actually leave the market.

Grace Period

After the framework is published, how long will manufacturers have to comply? The FDA typically provides compliance windows for new regulatory requirements, ranging from 6 months to 2 years depending on complexity. The length of this period has not been announced.

State Adoption

Will states adopt the federal framework uniformly? Or will some states maintain stricter or more permissive standards? The patchwork risk remains even after federal action, particularly for states with established cannabis regulatory programs that may conflict with the new federal standards.

AAFCO Alignment

Will AAFCO update its ingredient definitions to include CBD as an approved animal feed ingredient in line with the federal framework? Without AAFCO adoption, state-level compliance remains complicated even for products that meet federal standards.

Grandfathering

Will existing products on the market receive any grandfathering protection, or must every product currently on shelves be reformulated and recertified? This is a critical question for brands that have invested heavily in current formulations and inventory.

Labeling Specifics

What exactly must a compliant label include? Total cannabinoid content? Per-serving CBD dose? THC test results? Extraction method? Source material? The labeling requirements will determine how much information consumers receive at the point of purchase.

Frequently Asked Questions

What is Section 781 of the FDA Modernization Act?

Section 781 is a provision of federal law that directs the FDA to establish a regulatory framework for cannabidiol (CBD) products intended for animal use by November 2026. It is the first federal legislation to specifically address CBD for pets. The framework is expected to include manufacturing standards, testing requirements, labeling rules, and THC limits for animal CBD products.

Is it still legal to buy CBD for my pet?

Yes. Buying and using CBD for your pet is not prohibited. Section 781 targets the manufacture and sale of non-compliant products, not consumer purchase or possession. However, the products available to you will change once the regulatory framework is enforced. Full-spectrum products with THC above the 0.4 mg per-container threshold will likely need to be reformulated or withdrawn.

Does AAFCO approve CBD as a pet food ingredient?

No. AAFCO does not currently recognize CBD as an approved animal feed ingredient. This means that in states following AAFCO model regulations, CBD pet products may technically be considered adulterated animal feed. Whether AAFCO will update its ingredient definitions in response to the federal framework remains to be seen.

What does the NASC quality seal mean on a CBD product?

The NASC (National Animal Supplement Council) quality seal indicates that the manufacturer has passed an independent quality audit, carries liability insurance, maintains an adverse event reporting system, and submits to random product testing. It does not indicate FDA approval, does not verify the product works for any condition, and does not guarantee label accuracy for cannabinoid content. It is a positive quality signal but not a substitute for reviewing a product's third-party COA.

Can my veterinarian recommend CBD for my pet?

This depends on your state. Veterinary practice acts vary, and many states have not issued clear guidance on whether veterinarians can discuss or recommend CBD. Some veterinarians are comfortable discussing published research and general CBD use. Others avoid the topic due to legal ambiguity and liability concerns. Section 781's federal framework is expected to help by providing a clearer legal baseline, but it will not resolve all state-level ambiguities around veterinary CBD guidance.

When will enforcement of the new rules actually begin?

Section 781 sets a November 2026 deadline for the FDA to establish its framework. Enforcement is expected to follow in 2027, likely after a compliance grace period for manufacturers. The length of this grace period has not been announced. Based on precedent with similar FDA regulatory frameworks, 6 to 12 months is a reasonable expectation. The FDA may also miss the November 2026 deadline, which would push enforcement further out.